Fact Sheet: Oxytetracycline Medicated Feed for Shrimp INAD 8069

for detailed information, see INAD study protocol, use link on the left
last updated: 1 December 2011

The following links are specific to:
Medicated Feed for Shrimp

Drug summary & history

List of FDA-Approved drugs

Drug forms to be completed

Examples of completed forms

INAD study protocol

Material Safety Data Sheet

Study Summaries

What's the status of this drug's

Print this drug fact sheet

Print all drug fact sheets

Sign-up via the INAD Program Management System (IPMS)

Information on EPA's National Pollutant Discharge Elimination System (NPDES) Permits

Authorization & Categorical Exclusion Letters

Objective/purpose: Collect scientific data necessary to support pivotal efficacy trials to further establish the effectiveness of OTC to control bacterial diseases of marine penaeid shrimp species that occur under a variety of environmental conditions and over a range of temperatures.
Drug name: Oxytetracycline dihydrate (Terramycin 200® for Fish)
Source of drug: Phibro Animal Health
Address: 65 Challenger Road
Ridgefield, NJ 07660

Paul Duquette
Phone: 973-575-5255
Fax: 973-575-4354
email: paul.duquette@pahc.com

Target pathogen(s): Bacterial shrimp pathogens susceptible to oxytetracycline.
Method of administration: Medicated-feed treatment
Treatment dosage:

4.5 g oxytetracycline per kg of feed

Treatment regimen:

Medicated feed will be administered as a single treatment regimen, to be fed to satiation daily for 14 days.

A new treatment regimen may be initiated no sooner than five (5) days after the last treatment regimen has ended.

Withdrawal period:

2 days

No withdrawal period is required for treated shrimp what will be rendered.

Required test parameters:

Source data must be collected for at least 5 days before treatment, during treatment, and for at least 20 days after the treatment period (i.e., the post-treatment period) has ended.

Collection of this data is critically important. Samples of hepatopancreas or other typically affected tissue will be removed from groups of representative shrimp and tested by bacteriological, serological, or other methods to determine the presence of target pathogens.

Investigator should also report general shrimp behavior and any possible adverse effects relating to treatment.

Limitations or restrictions on use:

Investigator must follow all instructions in the Study Protocol for INAD 8069 regarding drug acquisition and handling, shrimp treatment and disposition, and data reporting requirements.

Drug discharge must be in compliance with local NPDES permitting requirements.

T200 will be administered as a single treatment regimen. A new treatment regimen may be initiated no sooner than five (5) days after the last treatment regimen ended.

Required INAD fee: $400.00 per facility per year
AADAP contact for other information: Ms. Bonnie Johnson, FWS - AADAP
Phone: 406-994-9905
Fax: 406-582-0242

Disclaimer: Product and company names mentioned in this website, or mentioned in materials accessed via this website, are for informational purposes only. The mention of such does not imply endorsement by the Aquatic Animal Drug Approval Partnership, the U.S. Fish & Wildlife Service or any other organization of the U.S. Government.